STX6 and cholangiocarcinoma: Overall, cancers with STX6 mutations were predominantly amplified mutations, notably cholangiocarcinoma (>8%), liver hepatocellular carcinoma (>8%), and breast invasive carcinoma (>7%) (Figure S1A).